A comparative study of orphan drug prices in Europe.
A comparative study of orphan drug prices in Europe.
复制标题
DOI：
10.1080/20016689.2017.1297886
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Toumi M
中科院分区：
文献类型：
--
作者：
Young KE;Soussi I;Hemels M;Toumi M
背景和目的：本研究通过比较法国、德国、意大利、挪威、西班牙、瑞典和英国类似可用孤儿药的年度治疗成本来评估价格差异。 方法：使用IHS POLI和国家价格数据库的出厂价格计算每种药物的年治疗成本。将比较国的治疗成本与英国进行比较，并分析比率。对疾病领域和英国成本四分位数进行子分析。 结果：共纳入孤儿药120种。与英国相比，法国（1.13）、德国（1.11）、意大利（1.08）、西班牙（1.07）的平均成本更高，瑞典（0.99）和挪威（0.88）的平均成本更低。平均比率提供了一个限制性的观点，因为比率非常不均匀（0.26至1.92），这也见于不同的疾病地区。平均比率在成本四分位数之间变化最小，这表明英国最昂贵和最便宜的孤儿药的成本差异相似。 结论：个别孤儿药的价格在欧洲国家之间差异很大，尽管平均而言这些差异相对较小。这项研究表明，在欧洲，我们可能无法预测哪个国家的孤儿药价格更高或更低。
Background and Objective: This study assessed price differences by comparing annual treatment costs of similarly available orphan drugs in France, Germany, Italy, Norway, Spain, Sweden, and UK. Methods: Annual treatment costs per drug were calculated using ex-factory prices from IHS POLI and country price databases. The treatment cost in the comparator country was compared to the UK and ratios were analysed. Subanalyses were done on disease areas and UK cost quartiles. Results: 120 orphan drugs were included. Compared to the UK, the average costs were more expensive in France (1.13), Germany (1.11), Italy (1.08), Spain (1.07), and were cheaper in Sweden (0.99) and Norway (0.88). The average ratios offered a restrictive view as ratios were greatly heterogeneous (0.26 to 1.92) which was also seen in the different disease areas. The averaged ratios varied minimally among the cost quartiles which shows that cost differences were similar for the most expensive and least expensive orphan drugs in the UK. Conclusions: Individual orphan drug prices can vary widely across European countries, although on average these differences are relatively minor. This study suggests that in Europe, we may not be able predict which country may have higher or lower prices for orphan drugs.